The Effects of Sleep Hypoxia on Coagulant Factors and Hepatic Inflammation in Emphysematous Rats

Abstract

Objectives

To develop a sleep hypoxia (SH) in emphysema (SHE) rat model and to explore whether SHE results in more severe hepatic inflammation than emphysema alone and whether the inflammation changes levels of coagulant/anticoagulant factors synthesized in the liver.

Methods

Seventy-five rats were put into 5 groups: SH control (SHCtrl), treated with sham smoke exposure (16 weeks) and SH exposure (12.5% O2, 3 h/d, latter 8 weeks); emphysema control (ECtrl), smoke exposure and sham SH exposure (21% O2); short SHE (SHEShort), smoke exposure and short SH exposure (1.5 h/d); mild SHE (SHEMild), smoke exposure and mild SH exposure (15% O2); standard SHE (SHEStand), smoke exposure and SH exposure. Therefore, ECtrl, SHEShort, SHEMild and SHEStand group were among emphysematous groups. Arterial blood gas (ABG) data was obtained during preliminary tests. After exposure, hepatic inflammation (interleukin -6 [IL-6] mRNA and protein, tumor necrosis factor α [TNFα] mRNA and protein) and liver coagulant/anticoagulant factors (antithrombin [AT], fibrinogen [FIB] and Factor VIII [F VIII]) were evaluated. SPSS 11.5 software was used for statistical analysis.

Results

Characteristics of emphysema were obvious in emphysematous groups and ABGs reached SH criteria on hypoxia exposure. Hepatic inflammation parameters and coagulant factors are the lowest in SHCtrl and the highest in SHEStand while AT is the highest in SHCtrl and the lowest in SHEStand. Inflammatory cytokines of liver correlate well with coagulant factors positively and with AT negatively.

Conclusions

When SH is combined with emphysema, hepatic inflammation and coagulability enhance each other synergistically and produce a more significant liver-derivative inflammatory and prothrombotic status.

About the Authors:

Jing Feng

Contributed equally to this work with: Jing Feng, Qing-shan Wang

Affiliations Respiratory Department, Tianjin Medical University General Hospital, Tianjin, China, Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina, United States of America

Qing-shan Wang

Contributed equally to this work with: Jing Feng, Qing-shan Wang

Affiliation: Institute of Toxicology, Shandong University, Jinan, Shandong, China

Ambrose Chiang

Affiliation: Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina, United States of America

Bao-yuan Chen

* E-mail: [email protected]

Affiliation: Respiratory Department, Tianjin Medical University General Hospital, Tianjin, China

Introduction

Chronic obstructive pulmonary disease (COPD), in which chronic systemic inflammation is a central component, is a growing global epidemic that is particularly important in developing countries [1]. It is expected that in 2020 COPD will become the third leading cause of death worldwide [2]. In humans, COPD includes two major subtypes, chronic bronchitis and emphysema. The emphysema subtype seems to present more obvious systemic inflammation, suggesting that it may be more prone to systemic consequences of COPD compared to subtype without emphysema [3]. Sleep hypoxemia (SH) in The International Classification of Sleep Disorders: Diagnostic and Coding Manual 2 (ICSD-2) is defined as “an SpO2 (oxyhemoglobin saturation) during sleep of >30% of total sleep time with an SpO2 of <90% in subject with a baseline awake SpO2 of ≥90% ”[4], [5]. The phenomenon of SH complicating emphysema has been recognized for at least 50 years [6] and has been noted in polysomnography (PSG) studies of emphysematous patients recently [7]. Because of a number of factors, mainly including: alveolar hypoventilation, airway obstruction, hyperinflation, respiratory muscle dysfunction, blunted ventilatory responses to hypoxia and ventilation-perfusion mismatch, emphysematous patients run a high risk of developing SH [8]–[10]. Compared to their non-SH brethren, emphysematous patients with SH have greater degrees of pulmonary hypertension and cor pulmonale [11], require more frequent hospitalizations, sustain higher mortality rates [12]–[15] and demonstrate systemic evidence of pronounced inflammatory activation [16] which may cause inflammatory damages to the liver as well.

Increased risk of thrombotic events occurs in COPD [17]. Venous thromboembolism (VTE) occurs with increased frequency in patients with COPD which may be due to hypercoagulability as a result of hypoxia [18]. Most of the coagulant factors and anticoagulant factors are synthesized in liver and among them, antithrombin (AT), fibrinogen (FIB) and Factor VIII (F VIII) play very important roles in coagulation cascade. AT, as a central anticoagulant in mammalian circulation system, binds and inactivates the serine proteases (Factors XIa, IXa, Xa, and thrombin) directly [19]; FIB, a soluble glycoprotein, is converted by thrombin into fibrin during blood coagulation and is then cross linked by factor XIII to form blood clot [20]; F VIII, an essential blood clotting factor also known as anti-hemophilic factor, is bound to von Willebrand factor (vWF) to form a stable complex in circulating blood and once activated by thrombin it dissociates from the complex to interact with Factor IXa and participates in the coagulation cascade for crosslinking into a blood clot. Without the protection of vWF, activated F VIII is proteolytically inactivated and cleared from the blood stream quickly [21].

Hypoxia induces systemic inflammation and acts as an aggravating factor of liver inflammation [22]–[24]. Compared with isolated emphysema, it has not yet been clearly elucidated whether SH in emphysema can cause more obvious inflammation in liver and whether the inflammation changes levels of coagulant/anticoagulant factors synthesized in the liver. To examine this, we exposed emphysematous rats (the pre-existing emphysema was formed through smoke exposure for 16 weeks) to hypoxia during sleep in a custom-made chamber therefore developing a novo rat model of SH in emphysema (SHE); with this model the inflammatory cytokines of the liver was studied and the four important coagulant/anticoagulant factors just mentioned above were measured. The inflammatory cytokines we measured in this study included interleukin -6 (IL-6, a classic pro-inflammatory cytokine) mRNA and protein levels, tumor necrosis factor α (TNFα, a classic pro-inflammatory cytokine) mRNA and protein levels.

Methods

The overall experimental protocol is hypoxia exposure during sleep on the base of pre-existing emphysema which is caused by 16 weeks of smoke exposure followed by exploring inflammatory and coagulant/anticoagulant factors of the liver. Institutional Review Board of Tianjin Medical University General Hospital approved the ethical and methodological aspects of the investigation (TMU IRB Approving Number: EA-20080002.).

Animal cigarette smoke exposure

Seventy-five male Wistar rats weighing 150∼180 g at age of 7 weeks (provided by Model Animal Center of Radiological Medicine Research Institute, Chinese Academy of Medical Science, license No.: SCXK Tianjin 2005-0001) were divided into 5 groups of 15 according to exposure conditions. Animals were housed in standard laboratory cages (5 per cage) and allowed food and water ad libitum. Rats were passively exposed to the smoke of 15 commercial unfiltered cigarettes (Daqianmen™, Yunnan, China) for 30 minutes twice daily, in the morning (before 9 am) and in the evening (after 5 pm), for 16 weeks (W 1 to the end of W 16) continuously in a custom-made plexiglas chamber (0.6 m3 with 5 poles in side wall for ventilation, 15 rats per batch). Content of tar was 18 mg for every cigarette and concentration of smog was about 15% (V/V) within the housing chamber through burning of 5 cigarettes concurrently. Control rats were exposed to a sham environment otherwise the same condition except of cigarette burning [25].

Animal electroencephalogram monitoring and SH exposure

A week prior to the experimental exposure, two stainless steel screws attached to insulated wires were implanted in the skull (from bregma: anteroposterior, +2 mm, mediolateral, −2 mm; and anteroposterior, −3 mm, mediolateral, +2 mm) of all recruited rats to record electroencephalogram (EEG) [26]. For electrophysiological recording, a lightweight shielded cable was connected to the plug on the rats' heads which permitted free movement of the rats within the cage. The signals were routed to an electroencephalograph (Nicolet Bravo, USA) so that sleep stages could be monitored conveniently and continuously. We designed a hypoxia pattern definitely different from intermittent hypoxia seen in previous literatures [27], [28] used in study on obstructive sleep apnea (OSA) and our focused hypoxia pattern was an “intermittent continuous hypoxia” often seen in SH of emphysematous patients [4], [5]. Briefly, a gas control delivery system [29] was designed to regulate the flow (2.5 L/min) of premixed gas (21% O2, 15% O2 or 12.5% O2) or clean air continuously into a customized SH housing chamber (volume about 10 L) to maintain a designated continuous hypoxia or normoxia environment. A series of programmable solenoids and flow regulators altered the fractional concentration of inspired oxygen through software edited with Visual C++ computer language that controlled the durations of hypoxia/normoxia cycles, which could divide total hypoxia time (1.5 h or 3 h) into 4 periods evenly (22.5 min or 45 min each) and distribute these hypoxia periods into physiological sleep time of Wistar rats identified by EEG (9 AM to 5 PM as estimated). The chamber was equipped with a humidifier, thermostat, and molecular sieve to maintain an inner temperature of 22 °C, humidity of ∼45% and a germfree circumstance. O2 and CO2 concentration monitors (Hamilton, Switzerland) were used to determine the environmental situation in the housing chamber for rats.

Exposure protocol

Seventy-five male Wistar rats were seperated into 5 groups of 15 as follows: A. SH control group (SHCtrl), sham smoke exposure (W 1 to W 16) and true SH exposure (12.5% O2, 3 h, W 9 to W 16); B. Emphysema control group (ECtrl), true smoke exposure (W 1 to W 16) and sham SH exposure (21% O2, 3 h, W 9 to W 16); C. Short SHE group (SHEShort), smoke exposure (W 1 to W 16) and short SH exposure (12.5% O2, 1.5 h, W 9 to W 16); D. Mild SHE group (SHEMild), smoke exposure (W 1 to W 16) and mild SH exposure (15% O2, 3 h, W 9 to W 16); E. Standard SHE group (SHEStand), smoke exposure (W 1 to W 16) and SH exposure (12.5% O2, 3 h, W 9 to W 16). Therefore, the ECtrl, SHEShort, SHEMild and SHEStand group were expected emphysematous groups according to experimental design.

Preliminary experiment to get the arterial blood gas (ABG)

Two days before the end of exposure period (end of W 16 – 2 d), 5 rats were selected randomly from each group to obtain ABG data. After anesthetization (10% chloral hydrate, 0.3 mL/100 g body weight intraperitoneally), the right femoral artery of selected rats was cannulated to obtain blood samples for monitoring ABG at anytime as necessary. At the end of treatment (end of W 16), arterial blood samples (0.7 mL each) were drawn under the following conditions:

Point 1: Wakefulness in SHCtrl group with clean air exposure (without emphysema, awake, 21% O2).

Point 2: Slow wave sleep period in SHCtrl group with clean air exposure (without emphysema, sleep, 21% O2).

Point 3: Slow wave sleep period in SHCtrl group with SH exposure (without emphysema, sleep, 12.5% O2).

Point 4: Wakefulness in ECtrl group with clean air exposure (emphysema, awake, 21% O2).

Point 5: Slow wave sleep period in ECtrl group with clean air exposure (emphysema, sleep, 21% O2).

Point 6: Slow wave sleep period in SHEMild group with SH exposure (emphysema, sleep, 15% O2).

Point 7: Slow wave sleep period in SHEStand group with SH exposure (emphysema, sleep, 12.5% O2).

For each blood sample collected, ABG analysis included measurements of partial oxygen pressure (PaO2), partial carbon dioxide pressure (PaCO2), arterial oxygen saturation (O2Sat) and pH value.

Measurements for AT, FIB, F VIII and vWF

The remaining 10 rats from each group were used for following experiments at the end of exposure. Blood samples were obtained from tail veins using sodium citrate in order to perform AT, FIB, F VIII and vWF tests through an ACL 9000 automated coagulation analyzer (Beckman Coulter, CA) with proper reagent kits (Dade Behring, IL) in the core hospital laboratory. Activities of AT and F VIII were measured in percent to standard plasma activity and concentration; the concentration of FIB was expressed as mg/dL; and the concentration of vWF Ag was reported as percentage in relation to a photometric extinction of standard plasma.

Histologic identification of emphysema

After anesthetization and isolation of lungs, all lung samples were inflated intrabronchially with 10% formalin at a constant transpulmonary pressure of 25 cm of formalin for at least 18 hours with samples impregnated wholly in formalin at the same time. Then lung blocks were fixed, embedded, cut and stained. Images were captured at 40 X and were saved as JPEG files [30]. Pictures were then given to pathologists with expertise in the pathology of emphysema for assessment.

Measurements for IL-6 mRNA and protein levels, TNFα mRNA and protein levels

For liver tissue preparation, blocks from each rat were frozen in liquid nitrogen and stored at −80°C in order to analyze IL-6 and TNFα. The levels of IL-6 and TNFα gene expression were quantified using real time RT-PCR analysis. Total RNA was isolated from rat liver samples using Trizol reagent, followed by purification with RNeasy Mini Kit (Qiagen, MD). Total RNA (1 µg) was reverse transcribed with murine leukemia virus reverse transcriptase and random hexamer primers. Primers for IL-6 and TNFα were designed using Primer Express software (version 2.0, Applied Biosystems, CA). The primer sequences used in this study were as follows: IL-6, 5′-CTG ATT GTA TGA ACA GCG ATG-3′ (forward) and 5′-GAA CTC CAG AAG ACC AGA GC-3′ (reverse); TNFa, 5′-GAC CCT CAC ACT CAG ATC ATC TTC T-3′ (forward) and 5′-CCT CCA CTT GGT GGT TTG CT-3′ (reverse); GAPDH, 5′-CCT GGA GAA ACC TGC CAA GTA T-3′ (forward) and 5′-AGC CCA GGA TGC CCT TTA GT-3′ (reverse). The SYBR green DNA PCR kit (Applied Biosystems, CA) was used for real time PCR analysis. Gene expression data was expressed using cycle time values normalized with internal GAPDH, and relative differences between control and treatment groups were calculated and expressed as relative increases setting control as 100%. The frozen liver blocks were also homogenized in 100 mg tissue/ml cold lysis buffer (20 mM Tris, 0.25 M sucrose, 2 mM EDTA, 10 mM EGTA, 1% Triton X-100 and 1 tablet of Complete Mini protease inhibitor cocktail/10 ml, Roche Diagnostics, IN). Homogenates were centrifuged at 100,000× g for 30 min, supernatant was collected, and total protein levels were determined using BCA protein assay reagent kit (PIERCE, WI). The protein levels of liver IL-6 and TNFα were measured with IL-6 and TNFα commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, MN).

Statistical Analysis

SPSS 11.5 (SPSS Inc., Chicago, IL) software package was used for statistical analysis and illustration. Preliminary ABG data was obtained and is displayed as a descriptive analysis. One way analysis of variance (ANOVA) was performed for whole difference and Bonferroni post hoc multiple comparisons were used to evaluate differences between internal groups. Linear correlation analysis and linear fitting were performed for influential power estimating to see whether significant correlations exist between relevant parameters. Unless otherwise stated, values were reported as mean ± standard deviation (SD), and P<0.05 is considered statistically significant.

Results

Figure 1 shows the pathologic pictures selected randomly from emphysematous rats. Pathologic characteristics of emphysema, though may be in different severities among groups, were obvious in the emphysematous rats, including inflammatory cell infiltration, increasing of mean linear intercept and decreasing of mean alveolar number per microscope field. (detail not provided in this article) [31]–[33].

[Figure omitted. See PDF.]

Figure 1. Pathologic pictures were obtained from emphysematous rats, stained with hematoxylin/eosin (H/E), and captured with 40 X light microscopy.

Scale at left lower represents the length of 1000 µm.

https://doi.org/10.1371/journal.pone.0013201.g001

Table 1 summarizes the ABG results obtained from preliminary experiments two days before the end of exposure period. The values in this table are descriptive, not for comparing between groups. PaO2 value of SHCtrl in SH(12.5%) is 55.083±0.3971 mmHg and PaO2 values of ECtrl in wakefulness, sleep, SH(15%) and SH(12.5%) are 84.467±3.6092, 73.400±2.1615, 54.617±2.0371 and 46.567±2.2844 mmHg, respectively.

[Figure omitted. See PDF.]

Table 1. Descriptive ABG results from preliminary tests.

https://doi.org/10.1371/journal.pone.0013201.t001

Table 2 demonstrates that all measured inflammatory parameters and coagulant factors are the lowest and AT (an anticoagulant factor) the highest in SHCtrl. Inflammatory cytokines and coagulant factors in SHEStand are the highest except for AT and vWF. AT in SHEStand has a tendency to be the lowest though does not attain statistical significance. For AT: SHCtrl is the highest; ECtrl is lower than SHCtrl, higher than SHEStand and not different with others; SHEStand is lower than SHCtrl and Ectrl but not different with SHEShort and SHEMild. For vWF: SHCtrl is the lowest; ECtrl is higher than SHCtrl, not different with SHEMild and lower than others; SHEStand is not different with SHEShort and higher than others. For FIB, F VIII, IL-6 mRNA, IL-6 protein, TNFα mRNA and TNFα protein: SHCtrl is the lowest; ECtrl is higher than SHCtrl and lower than SHEStand; SHEStand is the highest. More detail comparing results are shown in Table 2.

[Figure omitted. See PDF.]

Table 2. Coagulant/anticoagulant factors and hepatic inflammation status.

https://doi.org/10.1371/journal.pone.0013201.t002

For demonstrating clearly, Figure 2 plots this data showing that inflammatory cytokines of liver (represented with TNFα) and coagulant factors (represented with FIB) increase obviously from left to right (from SHCtrl to SHEStand, through other emphysematous groups) whereas anticoagulant factor, AT, shows the obverse tendency.

[Figure omitted. See PDF.]

Figure 2. TNFα protein and FIB increase from SHCtrl to SHEStand while AT shows the obverse tendency.

Error bars: +/− 1 SD. P<0.05 is considered statistically significant in Bonferroni post hoc multiple comparisons between internal groups. Unless otherwise stated, there is significant difference compared with other groups. * different with others; /not different with SHEMild; x not different with SHEShort; † not different with SHEShort and SHEMild; ‡ not different with ECtrl, SHEMild and SHEStand; § not different with ECtrl, SHEShort and SHEStand; || not different with SHEShort and SHEMild; # not different with ECtrl and SHEShort.

https://doi.org/10.1371/journal.pone.0013201.g002

From the relatively high correlation coefficients seen in Table 3, inflammatory cytokines of liver correlate very well with coagulant factors positively and with AT negatively. Figure 3 illustrates these correlations clearly. With the increasing of TNFα protein, FIB and F VIII increase gradually and AT decrease obviously. Correlation coefficients for TNFα protein with FIB, F VIII and AT are 0.853, 0.837 and −0.684, respectively, all P values <0.01.

[Figure omitted. See PDF.]

Figure 3. AT correlates with TNFα protein negatively. FIB and F VIII correlate with TNFα protein positively.

https://doi.org/10.1371/journal.pone.0013201.g003

[Figure omitted. See PDF.]

Table 3. Correlations between inflammatory parameters and coagulant factors/AT from liver.

https://doi.org/10.1371/journal.pone.0013201.t003

Discussion

Our model of emphysema, caused by smoke exposure and identified with pathologic criteria, reflects partly the pathobiologic features of emphysematous COPD which is induced commonly by inhalation of noxious gasses and particulate matter resulting in a chronic persistent inflammation in the lung [34]. This kind of chronic inflammatory response of the lung in some COPD patients may be associated with a significant systemic inflammatory response with downstream adverse clinical health effects, such as cardiovascular diseases, osteoporosis, diabetes, metabolic syndrome [1] and increased risk of hospitalization and mortality and is therefore a topic of increasing concern [35]. It has even been suggested that COPD might be a part of a chronic systemic inflammatory syndrome [36]. As the most important metabolic organ, most inflammatory materials are synthesized in liver. In a literature, it has been implicated that in COPD patients inflammatory mediators generated in the lung may “spill over” into the circulation and then activate the liver to release inflammatory proteins, which may be the real detrimental factors to target organs and the resource of systemic inflammation. Liver may play an important role in the COPD systemic inflammation chain [37]. Not only a pro-inflammatory status, COPD may also be in a pro-thrombotic status. There is an increased risk of thrombotic events occurs in those with COPD and our concerned coagulant factors, AT, FIB and F VIII, have all been influenced by COPD [38], [39]. In a cohort study of over 23,000 patients, Curkendall [40] reported an increased risk of acute myocardial infarction, stroke and pulmonary embolism in COPD. In a 5,451-patient deep venous thrombosis (DVT) registry, 668 (12.3%) had COPD as a comorbid condition [41]; and in 197 consecutive COPD patients, prevalence of pulmonary embolism was about 25% [42]. Though thrombosis is a multifactorial state and involves various processes such as platelet activation, endothelial cell injury, and activation of coagulation-fibrinolysis system, a hypercoagulative state may also be implicated with the increasing of these 3 hepatic factors we studied in the clotting system. Additionally, although it normally presents a nonthrombogenic surface, endothelium is capable of procoagulant activity and suppression of native anticoagulant properties. Exposure to hypoxic environments typically shifts the endothelial phenotype toward that in which anticoagulant characteristics are reduced and proinflammatory features dominate the endovascular milieu, therefore may increase procoagulant activity [43], [44] and inhibit fibrinolysis [45]. Inflammation that comes from hypoxia can promote the assembly of the prothrombinase complex and subsequently generates thrombin [46]. A study of healthy volunteers showed a transient increase in markers of coagulation activation during exposure to hypoxia [47]. Although these studies are done in vitro or in healthy volunteers, which may be unethical in COPD patients, further hypoxia, SH as an example, may worsen the preexisting pro-coagulant state in COPD as well putatively.

According to ABG results obtained from preliminary experiments and pathologic characteristics of smoke exposure rats, we have made a rat model of SHE through simulating the status of SH (with exposing rats to hypoxia during sleep period, as diagnostic criteria from ICSD-2 [4]–[7]) in emphysematous rats (caused by exposure to cigarette smoke for a long period of time and identified with pathologic criteria [31]–[33]). Our SHE model, in fact, is the “combination” of emphysema and SH, not a real COPD sleep related hypoxia (SRH) which appears at the end stage of COPD. In the real COPD SRH pattern, SRH is secondary to COPD, not combined by an exogenous hypoxia environment. As a rat model, for building a uniform hypoxia severity and time period, our exposure pattern may be a reasonable and feasible methodology and it does represent some of the pathological characteristics of SRH.

The coagulant factors (including vWF, a binder and protector of F VIII) and inflammatory parameters we measured are higher in emphysematous groups than those in SHCtrl when AT is higher in SHCtrl, indicating that, at least compared with simple SH, the emphysema (combined or not combined with SH) caused by smoke exposure may lead to a more severe inflammation and more obvious prothrombotic status. Among emphysematous groups, shown in table 2 and more clearly in Figure 2, inflammatory and prothrombotic tendency is significantly enhanced by SH, which is the evidence of synergism of emphysema and SH in this pathologic pathway. Because SHEStand has more severe inflammation and coagulabilty than SHEShort and SHEMild, we may conclude a dose-dependent mechanism in this synergism. In similar emphysema extent, the lower and longer time period of SH exposure, the more significant this synergism is.

In our study, inflammatory parameters of the liver correlate well with coagulant factors positively and with AT negatively. The potential influence of inflammation on coagulation may contribute further to thrombogenesis, while abnormal blood coagulation contributes directly to the pathophysiology and mortality of COPD, which means a more severe inflammatory state and a vicious cycle may be created [29]. Figure 3 illustrates and quantifies these correlations; it is clearly shown that with the increasing inflammation there may be an increase in blood coagulabilty.

As above mentioned, this SHE model represents some of the characteristics of SRH. In SRH, alveolar hypoventilation appears to play a major role, especially during rapid eye movement (REM) sleep. This was demonstrated by Becker [48] in a study of nine patients with underlying COPD. Compared with wakefulness, minute ventilation decreased 16% during non-REM sleep and 32% during REM sleep, predominantly because of a decrease in tidal volume, measured with a pneumotachograph. Additionally, arterial hypoxemia alone may be the product of worsening ventilation-perfusion mismatch with a greater effective shunt [5]. Alveolar hypoventilation occurs predominantly during REM sleep. Ventilation-perfusion mismatch can occur during non-REM sleep episodes as well [8].

Fletcher [49] showed that 27% of 135 patients with COPD with awake PaO2 exceeding 60 mm Hg had SRH. In another study, up to 25% of patients with COPD exhibit SRH, despite having a daytime PaO2 above 60 mm Hg [50]. Koo [51] found a mean decrease in PaO2 of 13.5 mm Hg and a mean increase of PaCO2 of 8.3 mm Hg during REM sleep in COPD subjects. In a study of 16 COPD patients [7], the mean SaO2 was 90±6% and the lowest SaO2 during the night was 83±8%. The percentage total sleep time (TST) with a SaO2 less than 90% was 37±45%. Sergi [12] found that SRH in COPD patients may represent an independent risk factor for the development of chronic respiratory failure in COPD patients with day-time PaO2 >60 mm Hg. Fletcher [13] noted significantly decreased survival among patients with SRH compared with those without. In a study focused on the systemic effects of nocturnal hypoxemia in COPD patients, the number of patients presenting C reactive protein (CRP) levels above those considered normal was significantly greater in the desaturation group which is the evidence of pronounced inflammatory activation in COPD patients with nocturnal hypoxemia. [16]

The necessity of treatment of isolated SRH in COPD has been debated for many years [52]. American Thoracic Society guidelines [53] for diagnosis and treatment of COPD recommended increasing oxygen flow by 1 L/min during sleep in patients undergoing long-term oxygen therapy (LTOT) to prevent nocturnal oxygen desaturation. However, those recommendations were not supported by some related studies. [9], [54], [55].

Through our study we can infer a potential pathologic pathway. In our emphysematous rat model, inflammatory mediators in liver increase and subsequently more coagulant factors are produced and AT is suppressed. When SH is combined with emphysema, synergistic effects appear, and the inflammation and coagulability may enhance each other and produce a more significant inflammatory and prothrombotic status which will lead to further health problems, as its clinical implication. In conclusion, the authors believe that along with optimal treatment for COPD, therapy for increasing PaO2 to >60 mm Hg is also important for the improvement of inflammation and coagulation, no matter what method is used (LTOT, nocturnal non-invasive positive pressure ventilation (NNIPPV), or medications).

Acknowledgments

We are grateful to the information and correction from Danielle Speer of Division of Pulmonary and Critical Care Medicine in Duke University Medical Center, Durham, North Carolina, USA.

Author Contributions

Conceived and designed the experiments: JF AC ByC. Performed the experiments: JF QsW. Analyzed the data: JF QsW. Wrote the paper: JF.

Citation: Feng J, Wang Q-s, Chiang A, Chen B-y (2010) The Effects of Sleep Hypoxia on Coagulant Factors and Hepatic Inflammation in Emphysematous Rats. PLoS ONE5(10): e13201. https://doi.org/10.1371/journal.pone.0013201

References

1. Barnes PJ (2010) Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 7: e1000220.PJ Barnes2010Chronic obstructive pulmonary disease: effects beyond the lungs.PLoS Med7e1000220

2. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L (2001) Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 68: 4–19.G. ViegiA. ScognamiglioS. BaldacciF. PistelliL. Carrozzi2001Epidemiology of chronic obstructive pulmonary disease (COPD).Respiration68419

3. Papaioannou AI, Mazioti A, Kiropoulos T, Tsilioni I, Koutsokera A, et al. (2010) Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med 104: 275–282.AI PapaioannouA. MaziotiT. KiropoulosI. TsilioniA. Koutsokera2010Systemic and airway inflammation and the presence of emphysema in patients with COPD.Respir Med104275282

4. American Academy of Sleep Medicine (2005) The international classification of sleep disorders: diagnostic and coding manual; 2nd ed. Westchester, IL: pp. 165–167.American Academy of Sleep Medicine2005The international classification of sleep disorders: diagnostic and coding manual; 2nd ed.Westchester, IL165167

5. Casey KR, Cantillo KO, Brown LK (2007) Sleep-related hypoventilation/hypoxemic syndromes. Chest 131: 1936–1948.KR CaseyKO CantilloLK Brown2007Sleep-related hypoventilation/hypoxemic syndromes.Chest13119361948

6. Kardos P, Keenan J (2006) Tackling COPD: a multicomponent disease driven by inflammation. MedGenMed 8: 54.P. KardosJ. Keenan2006Tackling COPD: a multicomponent disease driven by inflammation.MedGenMed854

7. Krachman SL, Chatila W, Martin UJ, Nugent T, Crocetti J, et al. (2005) Effects of lung volume reduction surgery on sleep quality and nocturnal gas exchange in patients with severe emphysema. Chest 128: 3221–3228.SL KrachmanW. ChatilaUJ MartinT. NugentJ. Crocetti2005Effects of lung volume reduction surgery on sleep quality and nocturnal gas exchange in patients with severe emphysema.Chest12832213228

8. Brijker F, van den Elshout FJ, Heijdra YF, Folgering HT (2001) Underestimation of nocturnal hypoxemia due to monitoring conditions in patients with COPD. Chest 119: 1820–1826.F. BrijkerFJ van den ElshoutYF HeijdraHT Folgering2001Underestimation of nocturnal hypoxemia due to monitoring conditions in patients with COPD.Chest11918201826

9. O'Donoghue FJ, Catcheside PG, Eckert DJ, McEvoy RD (2004) Changes in respiration in NREM sleep in hypercapnic chronic obstructive pulmonary disease. J Physiol 559: 663–673.FJ O'DonoghuePG CatchesideDJ EckertRD McEvoy2004Changes in respiration in NREM sleep in hypercapnic chronic obstructive pulmonary disease.J Physiol559663673

10. Orem JM, Lovering AT, Vidruk EH (2005) Excitation of medullary respiratory neurons in REM sleep. Sleep 28: 801–807.JM OremAT LoveringEH Vidruk2005Excitation of medullary respiratory neurons in REM sleep.Sleep28801807

11. Chaouat A, Naeije R, Weitzenblum E (2008) Pulmonary hypertension in COPD. Eur Respir J 32: 1371–1385.A. ChaouatR. NaeijeE. Weitzenblum2008Pulmonary hypertension in COPD.Eur Respir J3213711385

12. Sergi M, Rizzi M, Andreoli A, Pecis M, Bruschi C, et al. (2002) Are COPD patients with nocturnal REM sleep-related desaturations more prone to developing chronic respiratory failure requiring long-term oxygen therapy? Respiration 69: 117–122.M. SergiM. RizziA. AndreoliM. PecisC. Bruschi2002Are COPD patients with nocturnal REM sleep-related desaturations more prone to developing chronic respiratory failure requiring long-term oxygen therapy?Respiration69117122

13. Fletcher EC, Donner CF, Midgren B, Zielinski J, Levi-Valensi P, et al. (1992) Survival in COPD patients with a daytime PaO2 greater than 60 mm Hg with and without nocturnal oxyhemoglobin desaturation. Chest 101: 649–655.EC FletcherCF DonnerB. MidgrenJ. ZielinskiP. Levi-Valensi1992Survival in COPD patients with a daytime PaO2 greater than 60 mm Hg with and without nocturnal oxyhemoglobin desaturation.Chest101649655

14. Nunes DM, Mota RM, de Pontes Neto OL, Pereira ED, de Bruin VM, et al. (2009) Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung 187: 159–163.DM NunesRM MotaOL de Pontes NetoED PereiraVM de Bruin2009Impaired sleep reduces quality of life in chronic obstructive pulmonary disease.Lung187159163

15. Lewis CA, Fergusson W, Eaton T, Zeng I, Kolbe J (2009) Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax 64: 133–138.CA LewisW. FergussonT. EatonI. ZengJ. Kolbe2009Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep.Thorax64133138

16. Mueller Pde T, Gomes MD, Viegas CA, Neder JA (2008) Systemic effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep apnea syndrome. J Bras Pneumol 34: 567–574.T. Mueller PdeMD GomesCA ViegasJA Neder2008Systemic effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep apnea syndrome.J Bras Pneumol34567574

17. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, et al. (2009) Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 102: 1176–1182.A. UndasP. KaczmarekK. SladekE. StepienW. Skucha2009Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.Thromb Haemost10211761182

18. Sabit R, Thomas P, Shale DJ, Collins P, Linnane SJ (2010) The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. Chest 138: 47–51.R. SabitP. ThomasDJ ShaleP. CollinsSJ Linnane2010The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD.Chest1384751

19. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL (1994) Antithrombin: the principal inhibitor of thrombin. Semin Thromb Hemost 20: 353–372.RJ OldsDA LaneB. MilleV. ChowdhurySL Thein1994Antithrombin: the principal inhibitor of thrombin.Semin Thromb Hemost20353372

20. Doolittle RF (1984) Fibrinogen and fibrin. Annu Rev Biochem 53: 195–229.RF Doolittle1984Fibrinogen and fibrin.Annu Rev Biochem53195229

21. Sadler JE (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67: 395–424.JE Sadler1998Biochemistry and genetics of von Willebrand factor.Annu Rev Biochem67395424

22. Gonzalez NC, Wood JG (2010) Alveolar hypoxia-induced systemic inflammation: what low PO(2) does and does not do. Adv Exp Med Biol 662: 27–32.NC GonzalezJG Wood2010Alveolar hypoxia-induced systemic inflammation: what low PO(2) does and does not do.Adv Exp Med Biol6622732

23. Chao J, Wood JG, Gonzalez NC (2009) Alveolar hypoxia, alveolar macrophages, and systemic inflammation. Respir Res 10: 54.J. ChaoJG WoodNC Gonzalez2009Alveolar hypoxia, alveolar macrophages, and systemic inflammation.Respir Res1054

24. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M (2009) Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 35: 1397–1405.V. FuhrmannN. KneidingerH. HerknerG. HeinzM. Nikfardjam2009Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients.Intensive Care Med3513971405

25. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, et al. (2005) Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 172: 987–993.JH LeeDS LeeEK KimKH ChoeYM Oh2005Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs.Am J Respir Crit Care Med172987993

26. Horner RL, Sanford LD, Annis D, Pack AI, Morrison AR (1997) Serotonin at the laterodorsal tegmental nucleus suppresses rapid-eye-movement sleep in freely behaving rats. J Neurosci 17: 7541–7552.RL HornerLD SanfordD. AnnisAI PackAR Morrison1997Serotonin at the laterodorsal tegmental nucleus suppresses rapid-eye-movement sleep in freely behaving rats.J Neurosci1775417552

27. Feng J, Chen BY, Cui LY, Wang BL, Liu CX, et al. (2009) Inflammation status of rabbit carotid artery model endothelium during intermittent hypoxia exposure and its relationship with leptin. Sleep Breath 13: 277–283.J. FengBY ChenLY CuiBL WangCX Liu2009Inflammation status of rabbit carotid artery model endothelium during intermittent hypoxia exposure and its relationship with leptin.Sleep Breath13277283

28. Feng J, Chen BY, Guo MN, Cao J, Zhao HY, et al. (2007) Changes of nuclear factor-kappaB and intercellular adhesion molecule-1 in endothelial cells exposed to various intermittent hypoxia. Zhonghua Jie He He Hu Xi Za Zhi 30: 202–206.J. FengBY ChenMN GuoJ. CaoHY Zhao2007Changes of nuclear factor-kappaB and intercellular adhesion molecule-1 in endothelial cells exposed to various intermittent hypoxia.Zhonghua Jie He He Hu Xi Za Zhi30202206

29. Feng J, Chen BY, Guo MN, Cao J, Zhao HY, et al. (2007) Interleukin-6 and tumor necrosis factor-alpha levels of endothelial cells in different hypoxia modes: in vitro experiment. Zhonghua Yi Xue Za Zhi 87: 774–777.J. FengBY ChenMN GuoJ. CaoHY Zhao2007Interleukin-6 and tumor necrosis factor-alpha levels of endothelial cells in different hypoxia modes: in vitro experiment.Zhonghua Yi Xue Za Zhi87774777

30. Wagner U, Staats P, Fehmann HC, Fischer A, Welte T, et al. (2006) Analysis of airway secretions in a model of sulfur dioxide induced chronic obstructive pulmonary disease (COPD). J Occup Med Toxicol 1: 12.U. WagnerP. StaatsHC FehmannA. FischerT. Welte2006Analysis of airway secretions in a model of sulfur dioxide induced chronic obstructive pulmonary disease (COPD).J Occup Med Toxicol112

31. Thurlbeck WM (1967) Internal surface area and other measurements in emphysema. Thorax 22: 483–496.WM Thurlbeck1967Internal surface area and other measurements in emphysema.Thorax22483496

32. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, et al. (1978) The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 298: 1277–1281.M. CosioH. GhezzoJC HoggR. CorbinM. Loveland1978The relations between structural changes in small airways and pulmonary-function tests.N Engl J Med29812771281

33. Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, et al. (2005) Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-kappaB pathway activation. Am J Respir Crit Care Med 172: 74–84.MA BirrellS. WongDJ HeleK. McCluskieE. Hardaker2005Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-kappaB pathway activation.Am J Respir Crit Care Med1727484

34. Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165–1185.PJ BarnesBR Celli2009Systemic manifestations and comorbidities of COPD.Eur Respir J3311651185

35. Mannino DM, Thorn D, Swensen A, Holguin F (2008) Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32: 962–969.DM ManninoD. ThornA. SwensenF. Holguin2008Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD.Eur Respir J32962969

36. Fabbri LM, Rabe KF (2007) From COPD to chronic systemic inflammatory syndrome? Lancet 370: 797–799.LM FabbriKF Rabe2007From COPD to chronic systemic inflammatory syndrome?Lancet370797799

37. van Eeden SF, Sin DD (2008) Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 75: 224–238.SF van EedenDD Sin2008Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease.Respiration75224238

38. Vaidyula VR, Criner GJ, Grabianowski C, Rao AK (2009) Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res 124: 259–261.VR VaidyulaGJ CrinerC. GrabianowskiAK Rao2009Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease.Thromb Res124259261

39. Tapson VF (2005) The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 71–77.VF Tapson2005The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease.Proc Am Thorac Soc27177

40. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, et al. (2006) Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16: 63–70.SM CurkendallC. DeLuiseJK JonesS. LanesMR Stang2006Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients.Ann Epidemiol166370

41. Goldhaber SZ, Tapson VF; DVT FREE Steering Committee (2004) A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 93: 259–262.SZ GoldhaberTapson VF; DVT FREE Steering Committee2004A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.Am J Cardiol93259262

42. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, et al. (2006) Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 144: 390–396.I. Tillie-LeblondCH MarquetteT. PerezA. ScherpereelC. Zanetti2006Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors.Ann Intern Med144390396

43. Ten VS, Pinsky DJ (2002) Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 8: 242–250.VS TenDJ Pinsky2002Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction.Curr Opin Crit Care8242250

44. Gertler JP, Weibe DA, Ocasio VH, Abbott WM (1991) Hypoxia induces procoagulant activity in cultured human venous endothelium. J Vasc Surg 13: 428–433.JP GertlerDA WeibeVH OcasioWM Abbott1991Hypoxia induces procoagulant activity in cultured human venous endothelium.J Vasc Surg13428433

45. Gertler JP, Perry L, L'Italien G, Chung-Welch N, Cambria RP, et al. (1993) Ambient oxygen tension modulates endothelial fibrinolysis. J Vasc Surg 18: 939–946.JP GertlerL. PerryG. L'ItalienN. Chung-WelchRP Cambria1993Ambient oxygen tension modulates endothelial fibrinolysis.J Vasc Surg18939946

46. Rota S, McWilliam NA, Baglin TP, Byrne CD (1998) Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 91: 508–515.S. RotaNA McWilliamTP BaglinCD Byrne1998Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E.Blood91508515

47. Bendz B, Rostrup M, Sevre K, Andersen TO, Sandset PM (2000) Association between acute hypobaric hypoxia and activation of coagulation in human beings. Lancet 356: 1657–1658.B. BendzM. RostrupK. SevreTO AndersenPM Sandset2000Association between acute hypobaric hypoxia and activation of coagulation in human beings.Lancet35616571658

48. Becker HF, Piper AJ, Flynn WE, McNamara SG, Grunstein RR, et al. (1999) Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med 159: 112–118.HF BeckerAJ PiperWE FlynnSG McNamaraRR Grunstein1999Breathing during sleep in patients with nocturnal desaturation.Am J Respir Crit Care Med159112118

49. Fletcher EC, Miller J, Divine GW, Fletcher JG, Miller T (1987) Nocturnal oxyhemoglobin desaturation in COPD patients with arterial oxygen tensions above 60 mm Hg. Chest 92: 604–608.EC FletcherJ. MillerGW DivineJG FletcherT. Miller1987Nocturnal oxyhemoglobin desaturation in COPD patients with arterial oxygen tensions above 60 mm Hg.Chest92604608

50. Krachman S, Minai OA, Scharf SM (2008) Sleep abnormalities and treatment in emphysema. Proc Am Thorac Soc 5: 536–542.S. KrachmanOA MinaiSM Scharf2008Sleep abnormalities and treatment in emphysema.Proc Am Thorac Soc5536542

51. Koo KW, Sax DS, Snider GL (1975) Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease. Am J Med 58: 663–670.KW KooDS SaxGL Snider1975Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease.Am J Med58663670

52. O'Reilly P, Bailey W (2007) Long-term continuous oxygen treatment in chronic obstructive pulmonary disease: proper use, benefits and unresolved issues. Curr Opin Pulm Med 13: 120–124.P. O'ReillyW. Bailey2007Long-term continuous oxygen treatment in chronic obstructive pulmonary disease: proper use, benefits and unresolved issues.Curr Opin Pulm Med13120124

53. American Thoracic Society (1995) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152: S77–S121.American Thoracic Society1995Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med152S77S121

54. Plywaczewski R, Sliwinski P, Nowinski A, Kaminski D, Zieliński J (2000) Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest 117: 679–683.R. PlywaczewskiP. SliwinskiA. NowinskiD. KaminskiJ. Zieliński2000Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy.Chest117679683

55. Kim V, Benditt JO, Wise RA, Sharafkhaneh A (2008) Oxygen therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5: 513–518.V. KimJO BendittRA WiseA. Sharafkhaneh2008Oxygen therapy in chronic obstructive pulmonary disease.Proc Am Thorac Soc5513518